New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer

References

• Jeong K, Kang CS, Kim Y, et al. Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy. Cancer Lett. 2016;374(1):31–43. doi:10.1016/j.canlet.2016.01.05026854717
   PubMed Web of Science ®Google Scholar
• Min HS, Dong GY, Son S, et al. Echogenic glycol chitosan nanoparticles for ultrasound-triggered cancer theranostics. Theranostics. 2015;5(12):1402–1418. doi:10.7150/thno.1309926681985
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Controlled Release Off. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.030
   PubMed Web of Science ®Google Scholar
• Lakshmanan S, Gupta GK, Avci P, et al. Physical energy for drug delivery; poration, concentration and activation ☆. Adv Drug Deliv Rev. 2014;71(2):98–114. doi:10.1016/j.addr.2013.05.01023751778
   PubMedGoogle Scholar
• Steven M, Constantin C, Len S, et al. Ultrasound-enhanced drug delivery for cancer. Expert Opin Drug Deliv. 2012;9(12):1525–1538. doi:10.1517/17425247.2012.73960323121385
   PubMed Web of Science ®Google Scholar
• Annemieke VW, Ayache B, Michel V, et al. Micromanipulation of endothelial cells: ultrasound-microbubble-cell interaction. Ultrasound Med Biol. 2004;30(9):1255–1258. doi:10.1016/j.ultrasmedbio.2004.07.01515550330
   PubMed Web of Science ®Google Scholar
• Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007;9(9):415–447. doi:10.1146/annurev.bioeng.8.061505.09585217651012
   PubMedGoogle Scholar
• Sboros V. Response of contrast agents to ultrasound ☆. Adv Drug Deliv Rev. 2008;60(10):1117–1136. doi:10.1016/j.addr.2008.03.01118486270
   PubMed Web of Science ®Google Scholar
• Wu J, Nyborg W. Ultrasound, cavitation bubbles and their interaction with cells. Adv Drug Deliv Rev. 2008;60(10):1103–1116. doi:10.1016/j.addr.2008.03.00918468716
   PubMed Web of Science ®Google Scholar
• Vanbavel E. Effects of shear stress on endothelial cells: possible relevance for ultrasound applications. Prog Biophys Mol Biol. 2007;93(1):374–383. doi:10.1016/j.pbiomolbio.2006.07.01716970981
   PubMed Web of Science ®Google Scholar
• Delalande A, Kotopoulis S, Postema M, et al. Sonoporation: mechanistic insights and ongoing challenges for gene transfer. Gene. 2013;525(2):191–199. doi:10.1016/j.gene.2013.03.09523566843
   PubMed Web of Science ®Google Scholar
• Lentacker I, Cock ID, Deckers R, et al. Understanding ultrasound induced sonoporation: definitions and underlying mechanisms ☆. Adv Drug Deliv Rev. 2014;72:49–64. doi:10.1016/j.addr.2013.11.00824270006
   PubMed Web of Science ®Google Scholar
• Ingber DE. TENSEGRITY: THE ARCHITECTURAL BASIS OF CELLULAR MECHANOTRANSDUCTION. Annu Rev Physiol. 2003;59(1):575–599. doi:10.1146/annurev.physiol.59.1.575
   Google Scholar
• Apodaca G. Modulation of membrane traffic by mechanical stimuli. Am J Physiol Renal Physiol. 2002;282(2):F179. doi:10.1152/ajprenal.2002.282.2.F17911788431
   PubMed Web of Science ®Google Scholar
• Lionetti V, Fittipaldi A, Agostini S, et al. Enhanced caveolae-mediated endocytosis by diagnostic ultrasound in vitro. Ultrasound Med Biol. 2009;35(1):136–143. doi:10.1016/j.ultrasmedbio.2008.07.01118950933
   PubMed Web of Science ®Google Scholar
• Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev. 1995;75(3):519–560. doi:10.1152/physrev.1995.75.3.5197624393
   PubMed Web of Science ®Google Scholar
• Junru W. Theoretical study on shear stress generated by microstreaming surrounding contrast agents attached to living cells. Ultrasound Med Biol. 2002;28(1):125–129. doi:10.1016/S0301-5629(01)00497-511879959
   PubMed Web of Science ®Google Scholar
• Li Y, Wang P, Chen X, et al. Activation of microbubbles by low-intensity pulsed ultrasound enhances the cytotoxicity of curcumin involving apoptosis induction and cell motility inhibition in human breast cancer MDA-MB-231 cells. Ultrason Sonochem. 2016;33:26–36. doi:10.1016/j.ultsonch.2016.04.01227245953
   PubMed Web of Science ®Google Scholar
• Dubinsky TJ, Carlos C, Dighe MK, et al. High-intensity focused ultrasound: current potential and oncologic applications. AJR Am J Roentgenol. 2008;190(1):191–199. doi:10.2214/AJR.07.267118094311
   PubMed Web of Science ®Google Scholar
• Ji-Zhu X, Fang-Lin X, Li-Feng R, et al. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med Biol. 2012;38(8):1363–1371. doi:10.1016/j.ultrasmedbio.2012.03.00922633269
   PubMed Web of Science ®Google Scholar
• Deng Z, Xiao Y, Pan M, et al. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound. J Controlled Release. 2016;243:333–341. doi:10.1016/j.jconrel.2016.10.030
   PubMed Web of Science ®Google Scholar
• Wang X, Chen H, Zheng Y, et al. Au-nanoparticle coated mesoporous silica nanocapsule-based multifunctional platform for ultrasound mediated imaging, cytoclasis and tumor ablation. Biomaterials. 2013;34(8):2057–2068. doi:10.1016/j.biomaterials.2012.11.04423246067
   PubMed Web of Science ®Google Scholar
• Kilroy JP, Klibanov AL, Wamhoff BR, et al. Intravascular ultrasound catheter to enhance microbubble-based drug delivery via acoustic radiation force. Ultrason Ferroelectr Freq Control IEEE Trans. 2012;59(10):2156–2166. doi:10.1109/TUFFC.2012.2442
   PubMed Web of Science ®Google Scholar
• Kaya M, Toma C, Wang J, et al. Acoustic radiation force for vascular cell therapy: in vitro validation. Ultrasound Med Biol. 2012;38(11):1989–1997. doi:10.1016/j.ultrasmedbio.2012.07.01922975034
   PubMed Web of Science ®Google Scholar
• Toy R, Bauer L, Hoimes C, et al. Targeted nanotechnology for cancer imaging ☆. Adv Drug Deliv Rev. 2014;76(1):79–97. doi:10.1016/j.addr.2014.08.00225116445
   PubMedGoogle Scholar
• Theek B, Gremse F, Kunjachan S, et al. Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. J Controlled Release. 2014;182(1):83–89. doi:10.1016/j.jconrel.2014.03.007
   PubMedGoogle Scholar
• Shortencarier MJ, Dayton PA, Bloch SH, et al. A method for radiation-force localized drug delivery using gas-filled lipospheres. IEEE Trans Ultrason Ferroelectr Freq Control. 2004;51(7):822–831. doi:10.1109/TUFFC.2004.132074115301001
   PubMed Web of Science ®Google Scholar
• Fabian K, Stanley F, Jessica B, et al. Recent advances in molecular, multimodal and theranostic ultrasound imaging. Adv Drug Deliv Rev. 2014;72:15–27. doi:10.1016/j.addr.2013.11.01324316070
   PubMed Web of Science ®Google Scholar
• Chuang YH, Cheng PW, Li PC. Combining radiation force with cavitation for enhanced sonothrombolysis. IEEE Trans Ultrason Ferroelectr Freq Control. 2013;60(1):97–104. doi:10.1109/TUFFC.2013.254123287916
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Weinstein JN, Dennis WH, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202(4374):1290–1293. doi:10.1126/science.364652364652
   PubMed Web of Science ®Google Scholar
• Dou YN, Jinzi Z, Foltz WD, et al. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice. J Controlled Release Off. 2014;178(1):69–78. doi:10.1016/j.jconrel.2014.01.009
   PubMedGoogle Scholar
• Sun MP, Min SK, Park SJ, et al. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). J Controlled Release. 2013;170(3):373–379. doi:10.1016/j.jconrel.2013.06.003
   PubMed Web of Science ®Google Scholar
• Maples D, McLean K, Sahoo K, et al. Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy. Int J Hyperthermia. 2015;31(6):674–685. doi:10.3109/02656736.2015.105762226185910
   PubMed Web of Science ®Google Scholar
• Zhang N, Li J, Hou R, et al. Bubble-generating nano-lipid carriers for ultrasound/CT imaging-guided efficient tumor therapy. Int J Pharm. 2017;534(1):S0378517317306907. doi:10.1016/j.ijpharm.2017.07.081
   Google Scholar
• Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Rev Drug Discovery. 2014;13(11):813–827. doi:10.1038/nrd433325287120
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH Regulation in Tumours as a Therapeutic Strategy. Nature Rev Drug Discov. 2011.
   Google Scholar
• Hongjun LI, Wang J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems. Biotechnol Adv. 2014;32(4):789–803. doi:10.1016/j.biotechadv.2013.08.00223933109
   PubMed Web of Science ®Google Scholar
• Tan S, Wu T, Zhang D, et al. Cell or cell membrane-based drug delivery systems. Theranostics. 2015;5(8):863–881. doi:10.7150/thno.1185226000058
   PubMed Web of Science ®Google Scholar
• Jain RK; The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2015;4(1):1–23.
   Google Scholar
• Mani P, Grailer JJ, Srikanth P, et al. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials. 2009;30(30):6065–6075. doi:10.1016/j.biomaterials.2009.07.04819674777
   PubMed Web of Science ®Google Scholar
• Juan L, Yuran H, Anil K, et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32(4):693–710. doi:10.1016/j.biotechadv.2013.11.00924309541
   PubMed Web of Science ®Google Scholar
• Lv Y, Hao L, Hu W, et al. Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting. Sci Rep. 2016;6:29321. doi:10.1038/srep2932127378018
   PubMed Web of Science ®Google Scholar
• Luo W, Wen G, Yang L, et al. Dual-targeted and pH-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment. Theranostics. 2017;7(2):452–465. doi:10.7150/thno.1667728255342
   PubMed Web of Science ®Google Scholar
• Weitao Y, Weisheng G, Xiaoqun G, et al. Facile synthesis of Gd-Cu-In-S/ZnS bimodal quantum dots with optimized properties for tumor targeted fluorescence/MR in vivo imaging. ACS Appl Mater Interfaces. 2015;7(33):18759–18768. doi:10.1021/acsami.5b0537226257133
   PubMed Web of Science ®Google Scholar
• Weisheng G, Xiaolian S, Orit J, et al. Intrinsically radioactive [64Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence. ACS Nano. 2015;9(1):488–495. doi:10.1021/nn505660r25549258
   PubMed Web of Science ®Google Scholar
• Li C, Feng L, Zhang Y, et al. Real-time monitoring surface chemistry-dependent in vivo behaviors of protein nanocages via encapsulating an NIR-II Ag2S quantum dot. ACS Nano. 2015;9(12):12255. doi:10.1021/acsnano.5b0550326496067
   PubMed Web of Science ®Google Scholar
• Liming N, Xiaoyuan C. Structural and functional photoacoustic molecular tomography aided by emerging contrast agents. Chem Soc Rev. 2014;43(20):7132–7170. doi:10.1039/C4CS00086B24967718
   PubMed Web of Science ®Google Scholar
• Wang S, Lin J, Wang T, et al. Recent advances in photoacoustic imaging for deep-tissue biomedical applications. Theranostics. 2016;6(13):2394–2413. doi:10.7150/thno.1671527877243
   PubMed Web of Science ®Google Scholar
• Wanwan L, Xiaoyuan C. Gold nanoparticles for photoacoustic imaging. Nanomedicine. 2015;10(2):299–320. doi:10.2217/nnm.14.16925600972
   PubMed Web of Science ®Google Scholar
• Mayer KM, Hafner JH. Localized surface plasmon resonance sensors. Chem Rev. 2011;111(6):3828–3857. doi:10.1021/cr100313v21648956
   PubMed Web of Science ®Google Scholar
• Zhong J, Wen L, Yang S, et al. Imaging-guided high-efficient photoacoustic tumor therapy with targeting gold nanorods. Nanomed Nanotechnol Biol Med. 2015;11(6):1499–1509. doi:10.1016/j.nano.2015.04.002
   PubMed Web of Science ®Google Scholar
• Lin J, Chen X, Huang P. Graphene-based nanomaterials for bioimaging ☆. Adv Drug Deliv Rev. 2016;105(Pt B):242–254. doi:10.1016/j.addr.2016.05.01327233213
   PubMedGoogle Scholar
• Xuefeng Y, Gang N, Jing L, et al. Enhanced fluorescence imaging guided photodynamic therapy of sinoporphyrin sodium loaded graphene oxide. Biomaterials. 2015;42(42):94–102. doi:10.1016/j.biomaterials.2014.11.04025542797
   PubMedGoogle Scholar
• Huang P, Wang S, Wang X, et al. Surface functionalization of chemically reduced graphene oxide for targeted photodynamic therapy. J Biomed Nanotechnol. 2015;11(1):117. doi:10.1166/jbn.2015.205526301305
   PubMed Web of Science ®Google Scholar
• Lalwani G, Xin C, Nie L, et al. Graphene-based contrast agents for photoacoustic and thermoacoustic tomography ☆. Photoacoustics. 2013;1(3–4):62–67. doi:10.1016/j.pacs.2013.10.00124490141
   PubMedGoogle Scholar
• Kim H, Kim J, Lee M, et al. Photothermal gene delivery: stimuli-regulated enzymatically degradable smart graphene-oxide-polymer nanocarrier facilitating photothermal gene delivery. Adv Healthcare Mat. 2016;5(15):1917. doi:10.1002/adhm.201670080
   Web of Science ®Google Scholar
• Kalluru P, Vankayala R, Chiang C-S, et al. Nano-graphene oxide-mediated in vivo fluorescence imaging and bimodal photodynamic and photothermal destruction of tumors. Biomaterials. 2016;95:1–10. doi:10.1016/j.biomaterials.2016.04.00627108401
   PubMed Web of Science ®Google Scholar
• Li Z, Ke H, Wang J, et al. Graphene oxide and gadolinium-chelate functionalized Poly(lactic acid) nanocapsules encapsulating perfluorooctylbromide for ultrasound/magnetic resonance bimodal imaging guided photothermal ablation of cancer. J Nanosci Nanotechnol. 2016;16(3):2201. doi:10.1166/jnn.2016.1095027455619
   PubMed Web of Science ®Google Scholar
• Yang Y, Shi H, Wang Y, et al. Graphene oxide/manganese ferrite nanohybrids for magnetic resonance imaging, photothermal therapy and drug delivery. J Biomater Appl. 2016;30(6):810–822. doi:10.1177/088532821560192626296777
   PubMed Web of Science ®Google Scholar
• Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer. 2017;17(10):577–593. doi:10.1038/nrc.2017.7728912578
   PubMed Web of Science ®Google Scholar
• Nishida N, Kudo M. Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. Oncology. 2017;93(Suppl 1):160–164. doi:10.1159/00048124629258072
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013;4(1):81–89. doi:10.7150/thno.719324396516
   PubMed Web of Science ®Google Scholar
• Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst. 2007;99(14):1095–1106. doi:10.1093/jnci/djm04317623798
   PubMed Web of Science ®Google Scholar
• Min HS, You DG, Son S, et al. Echogenic glycol chitosan nanoparticles for ultrasound-triggered cancer theranostics. Theranostics. 2015;5(12):1402–1418. doi:10.7150/thno.1309926681985
   PubMed Web of Science ®Google Scholar
• Milane L, Ganesh S, Shah S, et al. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Controlled Release. 2011;155(2):237–247. doi:10.1016/j.jconrel.2011.03.032
   PubMed Web of Science ®Google Scholar
• Jennifer A, Andrew P, Caroline D, et al. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLoS One. 2013;8(6):e65304. doi:10.1371/journal.pone.006530423785417
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways ☆. Drug Resist Updat. 2011;14(3):191–201. doi:10.1016/j.drup.2011.03.00121466972
   PubMed Web of Science ®Google Scholar
• Mayer A, Vaupel P. Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol. 2013;789:203–209.23852496
   PubMed Web of Science ®Google Scholar
• Milane L, Duan Z, Amiji M. Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int. 2011;11(1):3. doi:10.1186/1475-2867-11-321320311
   PubMedGoogle Scholar
• Moen I, Stuhr LEB. Hyperbaric oxygen therapy and cancer—a review. Target Oncol. 2012;7(4):233–242. doi:10.1007/s11523-012-0233-x23054400
   PubMed Web of Science ®Google Scholar
• Moen I, Tronstad KJ, Kolmannskog O, et al. Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. BMC Cancer. 2009;9(1):1–9. doi:10.1186/1471-2407-9-44619118499
   PubMedGoogle Scholar
• Liu L, Chang S, Sun J, et al. Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts. Cancer Lett. 2015;361(1):147–154. doi:10.1016/j.canlet.2015.02.05225754815
   PubMed Web of Science ®Google Scholar
• Sun J, Yin M, Zhu S, et al. Ultrasound-mediated destruction of oxygen and paclitaxel loaded lipid microbubbles for combination therapy in hypoxic ovarian cancer cells. Ultrason Sonochem. 2016;28:319–326. doi:10.1016/j.ultsonch.2015.08.00926384914
   PubMed Web of Science ®Google Scholar
• Dai F, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2):72–84. doi:10.1016/j.mvr.2007.05.00317560615
   PubMed Web of Science ®Google Scholar
• Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res. 1996;56(18):4264.8797602
   PubMed Web of Science ®Google Scholar
• Mcdonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62(18):5381.12235011
   PubMed Web of Science ®Google Scholar
• Chao Z, Pintong H, Ying Z, et al. Anti-tumor efficacy of ultrasonic cavitation is potentiated by concurrent delivery of anti-angiogenic drug in colon cancer. Cancer Lett. 2014;347(1):105–113. doi:10.1016/j.canlet.2014.01.02224530229
   PubMed Web of Science ®Google Scholar
• Chowdhury SM, Wang TY, Bachawal S, et al. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Controlled Release. 2016;238:272–280. doi:10.1016/j.jconrel.2016.08.005
   PubMed Web of Science ®Google Scholar
• Pu K. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. J Controlled Release Off. 2015;203:99–108. doi:10.1016/j.jconrel.2015.02.018
   PubMed Web of Science ®Google Scholar
• Husain SR, Han J, Au P, et al. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. 2015;22(12):554. doi:10.1038/cgt.2015.5826584531
   PubMed Web of Science ®Google Scholar
• Shillitoe EJ. Gene therapy: the end of the rainbow? Head Neck Oncol. 2009;1(1):7. doi:10.1186/1758-3284-1-719331651
   PubMedGoogle Scholar
• Tong AW, Jay CM, Neil S, et al. Systemic therapeutic gene delivery for cancer: crafting Paris’ arrow. Curr Gene Ther. 2009;9(1). doi:10.2174/156652309787354630
   Web of Science ®Google Scholar
• Michael R, Axel S, Luca B. Safety of gene therapy: new insights to a puzzling case. Curr Gene Ther. 2014;14(6):429–436.25245088
   PubMed Web of Science ®Google Scholar
• Doi K, Takeuchi Y. Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials. Uirusu. 2015;65(1):27–36. doi:10.2222/jsv.65.2726923955
   PubMedGoogle Scholar
• Tse LV, Sven MT, Aravind A. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opin Biol Ther. 2015;15(6):845–855. doi:10.1517/14712598.2015.103564525985812
   PubMed Web of Science ®Google Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295–304. doi:10.1038/gt.2009.14819907498
   PubMed Web of Science ®Google Scholar
• Chi H, Sum SW, Slavcev RA. Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Curr Gene Ther. 2014;14(4):309–329.25039613
   PubMed Web of Science ®Google Scholar
• Morille M, Passirani C, Vonarbourg A, et al. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24):3477–3496. doi:10.1016/j.biomaterials.2008.04.03618499247
   PubMed Web of Science ®Google Scholar
• Huang C, Zhang H, Bai R. Advances in ultrasound-targeted microbubble–mediated gene therapy for liver fibrosis. Acta Pharmaceutica Sinica B. 2017;7(4):447–452. doi:10.1016/j.apsb.2017.02.00428752029
   PubMed Web of Science ®Google Scholar
• Shufang C, Juan G, Jiangchuan S, et al. Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells. Ultrason Sonochem. 2013;20(1):171–179. doi:10.1016/j.ultsonch.2012.06.01522841613
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6):590–610. doi:10.1016/j.molonc.2012.09.00623102669
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Cancer J. 2012;48(3):S8–S9.
   Google Scholar
• Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–780. doi:10.1038/sj.bjc.660302316495913
   PubMed Web of Science ®Google Scholar
• Jovanovic M, Hengartner MO. miRNAs and apoptosis: rNAs to die for. Oncogene. 2006;25(46):6176–6187. doi:10.1038/sj.onc.120991217028597
   PubMed Web of Science ®Google Scholar
• Somesh B, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010;126(6):1283–1290. doi:10.1002/ijc.2501419877123
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60(1):167–179. doi:10.1146/annurev.med.59.053006.10470719630570
   PubMed Web of Science ®Google Scholar
• Ma L, Liu J, Shen J, et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010;9(7):554–561. doi:10.4161/cbt.9.7.1126720150764
   PubMed Web of Science ®Google Scholar
• Wei-Chih T, Paul Wei-Che H, Tsung-Ching L, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2010;49(5):1571–1582.
   Web of Science ®Google Scholar
• He J, Xie G, Tong J, et al. Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys. 2014;70(2):1343–1350. doi:10.1007/s12013-014-0062-x24898807
   PubMed Web of Science ®Google Scholar
• Shoumei B, Nasser MW, Bo W, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Bio Chem. 2009;284(46):32015. doi:10.1074/jbc.M109.01677419726678
   PubMed Web of Science ®Google Scholar
• Wang T, Shigdar S, Shamaileh HA, et al. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett. 2017;387:77–83. doi:10.1016/j.canlet.2016.03.04527045474
   PubMed Web of Science ®Google Scholar
• Napoleone F. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009;20(4):158–163. doi:10.1684/ecn.2009.017020167554
   PubMed Web of Science ®Google Scholar
• Costache MI, Ioana M, Iordache S, et al. VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med. 2015;53(3):199–208. doi:10.1515/rjim-2015-002726710495
   PubMedGoogle Scholar
• Carter JG, Gammons MVR, Damodaran G, et al. The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy. Angiogenesis. 2015;18(1):23–30. doi:10.1007/s10456-014-9444-325274272
   PubMed Web of Science ®Google Scholar
• Prakash V, Popel AS, Feilim MG. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25(1):1–19. doi:10.1016/j.cytogfr.2013.11.00224332926
   PubMed Web of Science ®Google Scholar
• Huang HY, Kuo WT, Chou MJ, et al. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mat Res Part A. 2011;97A(3):330–338. doi:10.1002/jbm.a.33055
   Web of Science ®Google Scholar
• Won Jong K, Christensen LV, Seongbong J, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther J Am Soc Gene Ther. 2006;14(3):343–350. doi:10.1016/j.ymthe.2006.03.022
   PubMed Web of Science ®Google Scholar
• Kim J, Kim SW, Kim WJ. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides. 2015;21(2):101–107. doi:10.1089/oli.2011.0278
   Google Scholar
• Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nature Revi Genet. 2001;2(2):110–119. doi:10.1038/35052556
   PubMed Web of Science ®Google Scholar
• Florinas S, Kim J, Nam K, et al. Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release. 2014;183:1–8. doi:10.1016/j.jconrel.2014.03.02524657947
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nature Rev Cancer. 2008;8(1):61–70. doi:10.1038/nrc229318075512
   PubMed Web of Science ®Google Scholar
• Waligã Rska-Stachura J, Jankowska A, Waå›Ko R, et al. Survivin–prognostic tumor biomarker in human neoplasms–review. Ginekol Pol. 2012;83(7):537–540.22880480
   PubMed Web of Science ®Google Scholar
• Tanaka K. Iwamoto S. Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1):127–134.10656440
   PubMed Web of Science ®Google Scholar
• Grossman D, Mcniff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113(6):1076–1081. doi:10.1046/j.1523-1747.1999.00776.x10594755
   PubMed Web of Science ®Google Scholar
• Chang JY, Chang YC, Tsai FY, et al. Survivin – biology and potential as a therapeutic target in oncology. Oncotargets Ther. 2013;6(default):1453–1462. doi:10.2147/OTT.S33374
   PubMedGoogle Scholar
• Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15(2):2494–2516. doi:10.3390/ijms1502249424531137
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chang S, Sun J, et al. Targeted microbubbles for ultrasound mediated short hairpin RNA plasmid transfection to inhibit survivin gene expression and induce apoptosis of ovarian cancer A2780/DDP cells. Mol Pharm. 2015;12(9):3137–3145. doi:10.1021/mp500835z26212628
   PubMedGoogle Scholar
• Orzáez M, Gortat A, Sancho M, et al. Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain. Apoptosis. 2011;16(5):460–467. doi:10.1007/s10495-011-0582-421340509
   PubMed Web of Science ®Google Scholar
• Jingguo L, Du C, Tinghui Y, et al. Copolymer of poly(ethylene glycol) and poly(L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery. Nanoscale. 2014;6(3):1732–1740. doi:10.1039/C3NR05024F24346086
   PubMed Web of Science ®Google Scholar
• Wang P, Yin T, Li J, et al. Ultrasound-responsive microbubbles for sonography-guided siRNA delivery. Nanomedicine. 2016;12(4):1139–1149. doi:10.1016/j.nano.2015.12.36126733262
   PubMed Web of Science ®Google Scholar
• Gheath A, Haroon J, Stafford PD, et al. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645. doi:10.1517/14740338.2013.79594423668362
   PubMed Web of Science ®Google Scholar
• Mohammed S, Bakshi N, Chaudri N, et al. Cancer vaccines: past, present, and future. Adv Anat Pathol. 2016;23(3):180–191. doi:10.1097/PAP.000000000000011627058246
   PubMed Web of Science ®Google Scholar
• Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Expert Rev Vaccines. 2013;12(10):1125–1126. doi:10.1586/14760584.2013.83776024093953
   PubMed Web of Science ®Google Scholar
• Alex K. Overview of cancer vaccines: considerations for development. Hum Vaccin Immunother. 2012;8(9):1335–1353. doi:10.4161/hv.2051822894970
   PubMed Web of Science ®Google Scholar
• Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1(1):12. doi:10.1186/2051-1426-1-1224829749
   PubMedGoogle Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38–48. doi:10.1016/j.immuni.2013.07.00423890062
   PubMed Web of Science ®Google Scholar
• Dewitte H, Van Lint S, Heirman C, et al. The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy. J Control Release. 2014;194:28–36. doi:10.1016/j.jconrel.2014.08.01125151979
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P. et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949):1465–1468.1690918
   PubMed Web of Science ®Google Scholar
• Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA. 1994;91(20):9519–9523. doi:10.1073/pnas.91.20.95197937799
   PubMed Web of Science ®Google Scholar
• Chudley L, Mccann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8 T-cell responses and increases PSA doubling time. Cancer Immunol Immunother. 2012;61(11):2161–2170. doi:10.1007/s00262-012-1270-022729556
   PubMed Web of Science ®Google Scholar
• Diaz CM, Chiappori A, Aurisicchio L, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013;11(1):62. doi:10.1186/1479-5876-11-6223497415
   PubMedGoogle Scholar
• Butterfield LH, Economou JS, Gamblin TC, et al. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12(1):1–9. doi:10.1186/1479-5876-12-8624387290
   PubMedGoogle Scholar
• Lee SH, Danishmalik SN, Sin JI. DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother. 2015;11(8):1889–1900. doi:10.1080/21645515.2015.103550225984993
   PubMed Web of Science ®Google Scholar
• Un K, Kawakami S, Suzuki R, et al. Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier. Mol Pharm. 2011;8(2):543–554. doi:10.1021/mp100369n21250746
   PubMedGoogle Scholar
• Yoshida M, Kawakami S, Kono Y, et al. Enhancement of the anti-tumor effect of DNA vaccination using an ultrasound-responsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes. Int J Pharm. 2014;475(1–2):401–407. doi:10.1016/j.ijpharm.2014.09.00525218184
   PubMedGoogle Scholar
• Brollo J, Curigliano G, Disalvatore D, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39(1):44–50. doi:10.1016/j.ctrv.2012.03.00922541668
   PubMed Web of Science ®Google Scholar
• Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA. 2006;103(31):11719–11723. doi:10.1073/pnas.060431810316868082
   PubMed Web of Science ®Google Scholar
• Park EJ, Zhang YZ, Vykhodtseva N, et al. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J Control Release. 2012;163(3):277–284. doi:10.1016/j.jconrel.2012.09.00723000189
   PubMed Web of Science ®Google Scholar
• Kobus T, Zervantonakis IK, Zhang Y, et al. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. J Control Release. 2016;238:281–288. doi:10.1016/j.jconrel.2016.08.00127496633
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Richard S, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233. doi:10.1200/JCO.2008.16.544918809613
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-011621498393
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Rev Immunol. 2012;12(4):269–281. doi:10.1038/nri319122437939
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Yoshihiro H, Kazuyoshi T, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Rev Cancer. 2002;2(11):850–861. doi:10.1038/nrc92812415255
   PubMed Web of Science ®Google Scholar
• Christoph U, Torsten T, Barbara U, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100(4):1265–1273. doi:10.1182/blood.V100.4.1265.h81602001265_1265_127312149207
   PubMed Web of Science ®Google Scholar
• Alkins R, Burgess A, Ganguly M, et al. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res. 2013;73(6):1892–1899. doi:10.1158/0008-5472.CAN-12-260923302230
   PubMed Web of Science ®Google Scholar
• Alkins R, Burgess A, Kerbel R, et al. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol. 2016;18(7):974–981. doi:10.1093/neuonc/nov31826819443
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925–931. doi:10.1038/ni.240622990890
   PubMed Web of Science ®Google Scholar
• Suzuki R, Namai E, Oda Y, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release. 2010;142(2):245–250. doi:10.1016/j.jconrel.2009.10.02719883708
   PubMed Web of Science ®Google Scholar
• Chen PY, Hsieh HY, Huang CY, et al. Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. J Transl Med. 2015;13:93. doi:10.1186/s12967-015-0451-y25784614
   PubMed Web of Science ®Google Scholar